0000899243-18-030928.txt : 20181213 0000899243-18-030928.hdr.sgml : 20181213 20181213181448 ACCESSION NUMBER: 0000899243-18-030928 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181213 DATE AS OF CHANGE: 20181213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BridgeBio Pharma LLC CENTRAL INDEX KEY: 0001743881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 181234160 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-12-10 2018-12-12 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001743881 BridgeBio Pharma LLC 421 KIPLING ST. PALO ALTO CA 94301 0 0 1 0 Common Stock 2018-12-10 4 P 0 37989 13.29 A 22586636 D Common Stock 2018-12-10 4 P 0 2664 13.96 A 22589300 D All shares of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the "IPO"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part, (Continued from footnote 1) any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO. Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Due to a clerical error, the Form 4 filed on December 12, 2018 inadvertently reflected a transaction code of "S" instead of "P" to reflect that the shares were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 12, 2018 Form 4 remains correct. BridgeBio Pharma LLC, By: /s/ Neil Kumar, Name: Neil Kumar, Title: Chief Executive Officer 2018-12-13